ALLOGENE THERAPEUTICS INC. - COMMON STOCK

1,4400

04-апреля-25 16:45:00

15 мин. задержка

Акции

+0,0600

+4,35%

Сегодняшний диапазон

1,3200 - 1,4600

ISIN

N/A

Источник

NASDAQ

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

08 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

07 авг 2024 16:02:54 Источник Nasdaq GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

31 июл 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

01 июл 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

20 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

23 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

13 май 2024 16:47:42 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

13 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

06 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

26 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Announces Q2 Investor Conference Participation

09 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

14 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

12 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

05 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

28 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

16 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

16 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 янв 2024 16:15:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

04 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.